Author | Andrew Parece


Pricing for Rare Disease and Curative Therapies: What’s Fair?


There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.

Raising the Stakes On Value-Based Pricing

Pharmaceutical Executive


The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .